Lake Street lowered the firm’s price target on BioLife Solutions to $25 from $34 and keeps a Buy rating on the shares to reflect reduced revenue estimates after the company reported Q2 revenues that missed the firm’s estimate and consensus and lowered guidance to reflect macro pressures.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BLFS:
- BioLife Solutions price target lowered to $25 from $29 at TD Cowen
- BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business
- BLFS Upcoming Earnings Report: What to Expect?
- BioLife Solutions price target raised to $29 from $27 at Stephens
- Craig-Hallum starts BioLife Solutions at Buy with headwinds starting to subside
